Last reviewed · How we verify
Asparagic Acid (ASPARTIC ACID)
At a glance
| Generic name | ASPARTIC ACID |
|---|---|
| Drug class | Amino Acid [EPC] |
| Target | Excitatory amino acid transporter 1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Hypokalemia
- Hypokalemia Prevention
Common side effects
- Nausea
- Pyrexia
- Hypertension
- Vomiting
- Hemoglobin decreased
- Protein total decreased
- Hypokalemia
- Blood potassium decreased
- Gamma-glutamyltransferase increased
- Hyperglycemia
- Blood alkaline phosphatase increased
- Blood calcium decreased
Key clinical trials
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2,PHASE3)
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Neurobiology of Suicide (PHASE2)
- Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder (PHASE2)
- Pharmacokinetics of Zelquistinel in Fasted or Fed State (PHASE1)
- A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder (PHASE2)
- The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules (PHASE4)
- Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Asparagic Acid CI brief — competitive landscape report
- Asparagic Acid updates RSS · CI watch RSS